Board Member
DiaMedica Therapeutics Inc. (DMAC)Equibles does not estimate personal net worth.
Get an email with a short summary when DiaMedica Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get DMAC alertsRick Pauls is recorded as CEO and Board Member at DiaMedica Therapeutics Inc. (DMAC). The newest filing on record that lists Rick Pauls as CEO and Board Member at DiaMedica Therapeutics Inc. (DMAC) is dated March 28, 2025. DiaMedica Therapeutics Inc. reported in an 8-K filed May 23, 2024 that Rick Pauls was appointed Director, effective May 22, 2024. The proxy statement of DiaMedica Therapeutics Inc. reports total compensation of $2,727,350 for Rick Pauls in fiscal 2025, including a base salary of $645,000. Disclosed compensation is on record for 8 fiscal years. Rick Pauls has spoken on 22 earnings calls and 1 other investor event across 1 company, most recently for DiaMedica Therapeutics Inc. on November 13, 2026. DiaMedica Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at DiaMedica Therapeutics Inc. includes James Parsons (Chairman), Charles Semba (Board Member), Charles Semba, M.D. (Board Member) and 7 others.
“The seven director nominees proposed by the Board were elected to serve as members of the Board until the next annual general meeting of shareholders and until their respective successors are duly elected and qualified by the following final voting results”
“With me today are Dr. Julie Kropp, our Chief Medical Officer, and Scott Kellen, our Chief Financial Officer. Since our last earnings call, we achieved two major clinical milestones.”
“With me this morning are Dr. Julie Kropp, our Chief Medical Officer, and Scott Kellen, our Chief Financial Officer. Q2 was an important quarter for Diomedica, with progress across DEM29 in early onset fetal growth restriction, preeclampsia, and acute ischemic stroke.”
“So what we're developing is a recombinant protein called tissue calocrine. It's a critical protein. It's in all of us. It turns out that patients that have or at risk of preeclampsia have low levels.”
“With me this morning are Dr. Julie Kropp, our Chief Medical Officer, and Scott Callen, our Chief Financial Officer. Given that our last call was only five weeks ago, we'll try to keep our remarks short.”
“Thank you, Morgan, and thank you all for joining us for our fiscal year 2025 earnings call. With me this morning are Dr. Julie Kroff, our Chief Medical Officer, and Scott Kellan, our Chief Financial Officer.”
Start not stated–present
Last confirmed March 28, 2025
Start not stated–present
Last confirmed March 28, 2025
Biotechnology · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | DiaMedica Therapeutics Inc. (DMAC) | President and Chief Executive Officer | $645,000 | $2,727,350 |
| 2024 | DiaMedica Therapeutics Inc. (DMAC) | President and Chief Executive Officer | $593,250 | $1,550,985 |
| 2023 | DiaMedica Therapeutics Inc. (DMAC) | President and Chief Executive Officer | $562,000 | $1,215,161 |
| 2022 | DiaMedica Therapeutics Inc. (DMAC) | President and Chief Executive Officer | $522,796 | $1,080,607 |
| 2021 | DiaMedica Therapeutics Inc. (DMAC) | President and Chief Executive Officer | $477,448 | $1,136,169 |
| 2020 | DiaMedica Therapeutics Inc. (DMAC) | President and Chief Executive Officer | $455,013 | $878,203 |
| 2019 | DiaMedica Therapeutics Inc. (DMAC) | President and Chief Executive Officer | $420,000 | $733,707 |
| 2018 | DiaMedica Therapeutics Inc. (DMAC) | President and Chief Executive Officer | $315,208 | $733,707 |
